A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression on or After Standard First-Line Therapy
Strickland, Andrew (Primary Chief Investigator (PCI))